retatrutide triple agonist glp-1 gip glucagon phase 3 2025 What Makes Powder a Breakthrough Triple-Agonist API? retatrutide triple agonist glp-1 gip

Although the etiology of depression has not been fully elucidated, current scientific data emphasize the role of neurotrophic factors deficiencies, disturbed homeostasis between the nervous system and the immune and endocrine systems, as well as disturbances in brain energy metabolism and dysfunctions in the gut-brain axis as important factors in the pathogenesis of this neuropsychiatric disorder

Were DPP-4 inhibitors the original GLP-1s

Ghazanfar H, Javed N, Qasim A, et al

German J, Cordioli M, Tozzo V, Urbut S, Arumae K, Smit RAJ, et al

Patients with established cardiovascular disease should receive a pharmacological treatment intensification with an agent that has demonstrated benefit in cardiovascular safety studies: In patients with pre-existing atherosclerotic cardiovascular disease (ASCVD), a GLP-1 receptor agonist, or SGLT-2 inhibitor with characterized cardiovascular safety should be used